Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained

　　Drug Overview and Therapeutic Positioning

　　Trametinib is a highly selective,reversible MEK1/2 kinase inhibitor that blocks phosphorylation-dependent activation of MEK proteins within the RAS-RAF-MEK-ERK signaling cascade,thereby suppressing tumor cell proliferation and inducing apoptosis.The drug occupies a central role in treating multiple solid tumors driven by BRAF V600 mutations,either as monotherapy or in combination with the BRAF inhibitor dabrafenib to achieve dual-target synergistic blockade.Critically,trametinib's efficacy is strictly dependent on the presence of BRAF V600E or V600K mutations;validated molecular testing confirming mutation-positive status is mandatory before initiation,and the drug is not indicated for patients with wild-type BRAF.

　　Refrigerated Storage Conditions and Shelf Life Management

　　Trametinib is temperature-sensitive and must be stored under refrigeration at 2°C to 8°C,protected from light and moisture.Medication should always remain in its original bottle with the cap tightly closed;transfer to alternative containers is prohibited.High-humidity environments such as bathrooms or kitchens must be avoided to prevent degradation from temperature and humidity fluctuations.Once removed from refrigeration,the dose should be administered within the specified timeframe to avoid prolonged room-temperature exposure.The shelf life is typically 24 to 36 months as indicated on packaging;expired medication must be disposed of according to medical waste regulations and should never be consumed.

　　Fasting Administration Protocol and Dose Integrity

　　Trametinib must be taken under strict fasting conditions:at least 1 hour before or at least 2 hours after any meal.Food,particularly high-fat meals,significantly reduces trametinib bioavailability,resulting in subtherapeutic plasma concentrations that directly compromise anti-tumor efficacy.Patients are advised to establish a fixed daily dosing time,such as 1 hour before breakfast,to maintain stable pharmacokinetic profiles.Tablets should be swallowed whole with adequate water;splitting,chewing,or crushing is strictly prohibited to preserve formulation integrity and absorption characteristics.If vomiting occurs after dosing,no additional dose should be taken;patients should simply continue with the next scheduled dose to avoid toxicity from duplicate administration.

　　Missed Dose Management Principles

　　When a dose of trametinib is missed,the appropriate action depends on the interval until the next scheduled dose.If more than 12 hours remain,the missed dose should be taken immediately.If less than 12 hours remain,the missed dose should be skipped entirely,and the regular schedule resumed at the next predetermined time.Under no circumstances should a double dose be taken to compensate for a missed one,as this increases the risk of severe adverse events.Patients are encouraged to use pill organizers,phone alarms,or medication management applications to establish reminder systems and minimize missed-dose occurrences.

　　Eligible Patient Populations and Approved Indications

　　Trametinib monotherapy is indicated for patients with BRAF V600E/V600K-mutant unresectable or metastatic melanoma who have not previously received BRAF inhibitor therapy.Combination therapy with dabrafenib encompasses a broader range of indications:first-line treatment and adjuvant therapy for BRAF V600E/V600K-mutant unresectable or metastatic melanoma;BRAF V600E-mutant non-small cell lung cancer(NSCLC);BRAF V600E-mutant anaplastic thyroid carcinoma(ATC);BRAF V600E-mutant solid tumors in patients aged 6 years and older;and BRAF V600E-mutant low-grade gliomas in patients aged 1 year and older.All indications require confirmed BRAF V600 mutation positivity via standardized molecular pathology testing prior to clinical decision-making.

　　Special Population Considerations

　　No starting dose adjustment is required for elderly patients(aged 65 and above);however,given reduced cardiovascular reserve,more frequent monitoring of left ventricular ejection fraction(LVEF)and other cardiac function parameters is warranted.Patients with mild to moderate hepatic impairment generally require no dose modification,while insufficient safety data exist for severe hepatic impairment,necessitating careful benefit-risk assessment.No dose adjustment is typically needed for patients with renal insufficiency.Trametinib is contraindicated during pregnancy and lactation;individuals of reproductive potential must employ highly effective contraception during treatment and for a defined period after discontinuation to prevent fetal exposure.